Total
0
Shares
Radient Technologies (TSXV:RTI) participates in medical cannabis study
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MediPharm Labs introduces CBD 100, THC 30 and the company’s first cannabinoid cannabinol (CBN) rich formula
  • MediPharm has also launched its next-generation oil products with its first unique CBN formula, CBN1:2 Nighttime Formula containing 10mg/ml of CBN and 20mg/ml of THC
  • These products will be available through retail channels in Ontario, British Columbia, Alberta, Manitoba and Saskatchewan
  • MediPharm Labs specializes in the production of pharmaceutical quality cannabis oil and concentrates
  • MediPharm Labs Corp. (LABS) is unchanged on the day, trading at C$0.47 per share at 11:00 am ET

MediPharm Labs Corp. (LABS) has launched CBD 100, THC 30 and the company’s first cannabinoid cannabinol (CBN) rich formula.

“MediPharm Labs is dedicated to developing innovative and customized formulated products that consumers can trust for their individual medicinal and wellness needs,” said Keith Strachan, President and Interim CEO, MediPharm Labs.

“Our latest release of new cannabinoid-based formulas, including our first formulation of minor cannabinoid CBN, enables us to fulfill increasing customer demand for more personalized products while maintaining our commitment to pharma-quality manufacturing.”

These new products are the latest in MediPharm Labs’ family of branded products, delivering a unique flavour profile from the naturally occurring cannabis terpenes, each using coconut/palm-based MCT carrier oil carefully chosen for sustainable practices and each produced according to our exacting manufacturing standards to ensure the highest purity and quality.

The new products include CBD100 Ultra Formula oil, containing the highest amount of CBD currently available at 100mg/ml and THC30 Plus Formula oil, containing 30mg/ml, the most potent format available under Health Canada’s regulations.

MediPharm also launched its next-generation oil products with its first unique CBN formula, CBN1:2 Nighttime Formula containing 10mg/ml of CBN and 20mg/ml of THC using full spectrum cannabis concentrate CBN.

CBN is typically found in only trace quantities in the cannabis plant but can be formed through the oxidation of THC.

Initial quantities will be available in the coming weeks for patients through Medical Cannabis by Shoppers and for consumers through retail channels in Ontario, British Columbia, Alberta, Manitoba and Saskatchewan.

MediPharm Labs plans to achieve full national distribution of its full suite of cannabis products becoming a “One-Stop-Shop” for retailers and distributors across Canada.

MediPharm Labs specializes in the production of purified, pharmaceutical quality cannabis oil and concentrates.

MediPharm Labs Corp. (LABS) is unchanged on the day, trading at C$0.47 per share at 11:00 am ET.

More From The Market Herald
BC Craft Supply Co. - CFO Anthony Laud - The Market Herald Canada

" BC Craft Supply (CSE:CRFT) appoints Anthony Laud as Chief Financial Officer

BC Craft Supply Co. (CRFT) has appointed Anthony Laud as its new Chief Financial Officer.
Dash Capital (TSXV:DCX.P) signs LOI for qualifying transaction

" TransCanna (CSE:TCAN) launches new revenue stream

TransCanna Holdings (TCAN) has onboarded its first client for third-party cold storage, Kase Manufacturing.
Simply Better Brands (TSXV:SBBC) acquires interest in the Crisp Group

" Simply Better Brands (TSXV:SBBC) acquires interest in the Crisp Group

Simply Better Brands (SBBC) has completed its acquisition of a 60 per cent interest in Crisp Management Group Inc.
Aleafia Health (TSX:AH) launches cannabis soft chews

" Pure Extracts (CSE:PULL) ships initial order of edible gummies to Alberta

Pure Extracts Technologies (PULL) has shipped its initial order of edible gummies to Alberta Gaming, Liquor & Cannabis (AGLC).